smoldering plasma cell myeloma
smoldering plasma cell myeloma
Explore linked clinical trials. Standard reference: MONDO:000523552 results ยท Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT07393282 | |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 1 | 2026-10-07 | NCT02886065 | |
| Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Not stated | 2026-10-07 | NCT02726750 | |
| Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Not stated | 2026-10-06 | NCT05136807 | |
| Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT02960555 | |
| A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2026-10-05 | NCT06055894 | |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, light chain deposition disease, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01169337 | |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, proteostasis deficiencies, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-25 | NCT06768489 | |
| A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Not applicable | 2026-09-21 | NCT04920084 | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | Abnormalities, Multiple, Blood Protein Disorders, Castleman disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, POEMS syndrome, Skin and Connective Tissue Diseases, amyloidosis, cardiovascular disorder, cryoglobulinemia, heavy chain deposition disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, light chain deposition disease, lymphatic system disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, plasma cell leukemia, plasma cell neoplasm, polyneuropathy, precancerous condition, proteostasis deficiencies, skin disorder, skin vascular disease, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-09-16 | NCT05283993 | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06183489 | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-08-26 | NCT00114101 | |
| Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Not yet recruiting | Not applicable | 2026-08-24 | NCT06987708 | |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 3 | 2026-08-19 | NCT03937635 | |
| Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not applicable | 2026-08-18 | NCT05831358 | |
| Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Early phase 1 | 2026-07-17 | NCT02603887 | |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-07-16 | NCT05469893 | |
| CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-07-13 | NCT06644625 | |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 2 | 2026-07-08 | NCT06140524 | |
| Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-07-06 | NCT07684274 | |
| Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Phase 2 | 2026-06-01 | NCT04776395 | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, myelodysplastic syndrome, myeloid leukemia, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-05-07 | NCT02269592 | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2026-05-05 | NCT01177527 | |
| FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, monoclonal gammopathy of uncertain significance, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Not applicable | 2026-05-01 | NCT07446777 | |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2026-04-30 | NCT05014646 |